Media

Presentations and Publications
 

OncoDefender-CRC reviewed in CANCER

Generation and External Validation of a Tumor-Derived 5-Gene Prognostic Signature for Recurrence of Lymph Node-Negative, Invasive Colorectal Carcinoma (PDF)

CONCLUSIONS: To the authors' knowledge, the 5-gene rule (OncoDefender-CRC) is the first molecular prognostic that has been validated in both stage I CRC and stage II colon cancer. It outperforms standard clinicopathologic prognostic criteria and obviates the need to retrieve 12 lymph nodes for accurate prognostication. It identifies those patients most likely to develop recurrent disease within 3 years after curative surgery and, thus, those most likely to benefit from adjuvant treatment.